---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-003357"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:46:08.354180+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics receives US patent for IV levosimendan in PH-HFpEF, expiring Dec 2040

## Summary
- U.S. Patent No. 11,607,412 covers IV levosimendan for pulmonary hypertension with HFpEF.
- Patent protection extends until December 2040, strengthening IP for levosimendan.
- No FDA-approved treatments exist for PH-HFpEF, which affects >1.6M North Americans.
- Levosimendan combines K+ATP channel activation and Ca++ sensitization, distinct MoA.
- HELP Study showed 29-meter improvement in 6-minute walk distance vs placebo (p=0.03).

## SEC filing metadata
- accession: 0001654954-23-003357
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495423003357/0001654954-23-003357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495423003357/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-003357
- JSON: https://secwatch.observer/filing/0001654954-23-003357.json
- Plain text: https://secwatch.observer/filing/0001654954-23-003357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.